This Article  • Full text  • PDF  • CME Course for This Article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in this journal  Topic Collections  • Patient Education/ Health Literacy  • Cardiovascular System  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

The CHECK-UP Study: A Randomized Controlled Trial

Steven A. Grover, MD, MPA, FRCPC; Ilka Lowensteyn, PhD; Lawrence Joseph, PhD; Mohammed Kaouache, MSc; Sylvie Marchand, RN; Louis Coupal, MSc; Ghislain Boudreau, PhD; for the Cardiovascular Health Evaluation to Improve Compliance and Knowledge Among Uninformed Patients (CHECK-UP) Study Group

Arch Intern Med. 2007;167(21):2296-2303.

Background  Despite increasing evidence that treating dyslipidemia reduces cardiovascular events, many patients do not achieve recommended lipid targets.

Methods  To determine whether showing physicians and patients the patient's calculated coronary risk can improve the effectiveness of treating dyslipidemia in a primary care setting, patients were randomized to receive usual care or ongoing feedback regarding their calculated coronary risk and the change in this risk after lifestyle changes, pharmacotherapy, or both to treat dyslipidemia. Outcomes, based on intention-to-treat analysis, included changes in blood lipid levels, coronary risk, and the frequency of reaching lipid targets.

Results  Two hundred thirty primary care physicians enrolled 3053 patients. After 12 months of follow-up, 2687 patients (88.0%) remained in the study. After adjustment for baseline lipid values, significantly greater mean reductions in low-density lipoprotein cholesterol levels and the total cholesterol to high-density lipoprotein cholesterol ratio were observed in patients receiving risk profiles (51.2 mg/dL [to convert to millimoles per liter, multiply by 0.0259] and 1.5, respectively) vs usual care (48.0 mg/dL and 1.3, respectively), but the differences were small (–3.3 mg/dL; 95% confidence interval [CI], –5.4 to –1.1 mg/dL; and –0.1; 95% CI, –0.2 to –0.1, respectively). Patients in the risk profile group were also more likely to reach lipid targets (odds ratio, 1.26; 95% CI, 1.07 to 1.48). A significant dose-response effect was also noted when the impact of the risk profile was stronger in those with worse profiles.

Conclusions  Discussing coronary risk with the patient is associated with a small but measurable improvement in the efficacy of lipid therapy. The value of incorporating risk assessment in preventive care should be further evaluated.

Author Affiliations: McGill Cardiovascular Health Improvement Program and the Divisions of General Internal Medicine and Clinical Epidemiology, The Montreal General Hospital, Departments of Medicine and Epidemiology and Biostatistics, McGill University (Drs Grover, Lowensteyn, and Joseph; Messrs Kaouache and Coupal; and Ms Marchand), and Pfizer Canada (Dr Boudreau), Montreal, Quebec, Canada.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Informing Patients of Their Coronary Risk
Afschin Gandjour
Arch Intern Med. 2008;168(15):1719.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Prediction Is Difficult, Particularly About the Future
Rod Jackson and Sue Wells
Arch Intern Med. 2007;167(21):2286-2287.
EXTRACT | FULL TEXT  

Using Cardiovascular Age Equivalent to Close the Treatment Gap for Dyslipidemia
Charles B. Eaton
Arch Intern Med. 2007;167(21):2288.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians.
Cooney et al.
J Am Coll Cardiol 2009;54:1209-1227.
ABSTRACT | FULL TEXT  

Cognitive Risks of Dyslipidemia
Terre
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2009;3:284-286.
ABSTRACT  

Patient Dialysis Knowledge Is Associated with Permanent Arteriovenous Access Use in Chronic Hemodialysis
Cavanaugh et al.
CJASN 2009;4:950-956.
ABSTRACT | FULL TEXT  

Evaluating cardiovascular risk assessment for asymptomatic people
Scott
BMJ 2009;338:a2844-a2844.
FULL TEXT  

Hypercholesterolemia, eligibility for lipid-lowering therapy and therapeutic success: population-based study in a Portuguese urban population
Alves and Azevedo
Eur J Endocrinol 2008;159:755-760.
ABSTRACT | FULL TEXT  

Tool to Assess Likelihood of Fasting Glucose ImpairmenT (TAG-IT)
Koopman et al.
Ann Fam Med 2008;6:555-561.
ABSTRACT | FULL TEXT  

Informing Patients of Their Coronary Risk
Gandjour
Arch Intern Med 2008;168:1719-1719.
FULL TEXT  

Do Coronary Risk Profiles Help Patients Reach Lipid Targets?
JWatch General 2008;2008:6-6.
FULL TEXT  

Prediction Is Difficult, Particularly About the Future
Jackson and Wells
Arch Intern Med 2007;167:2286-2287.
FULL TEXT  

Using Cardiovascular Age Equivalent to Close the Treatment Gap for Dyslipidemia
Eaton
Arch Intern Med 2007;167:2288-2288.
FULL TEXT